vTv Therapeutics
Presencia
MacAndrews & Forbes posee 4 subsidiarias incluyendo Savi, Siga Technologies y Vericast.
Ellos se encuentran en:
- Comunicación & Ventas40%
- Holding20%
- Otro40%
Ejecutivos
Ver el organigrama con sus 18 ejecutivos principales
Biografías más buscadas en vTv Therapeutics
- Paul Sekhri, President and Chief Executive Officer
- Fahed Al Marzooqi, Director
- Jonathan Isaacsohn, Director and Chairman of the Board
Recientes movimientos de ejecutivos en vTv Therapeutics
- Thomas Strack, se ha incorporado a la empresa como Chief Medical Officer (noticia publicada el 3 de noviembre de 2023).
Recientes movimientos de ejecutivos en MacAndrews & Forbes
- Julian Nemirovsky, Senior Vice President, Capital Markets, ha dejado la empresa (noticia publicada el 27 de diciembre de 2023).
Crear su alerta
para seguir los movimientos de los ejecutivos en vTv Therapeutics.
Farmacia
MacAndrews & Forbes tiene 1.859 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacia
- MedMen has filed for bankruptcy protection (publicado el 28 de abril de 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado el 23 de marzo de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado el 19 de marzo de 2024).
Otros contactos sugeridos en el sector Farmacia
Noticias
Últimos comunicados de prensa de vTv Therapeutics
- vTv Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer | vTv Therapeutics Inc.
- vTv Therapeutics Announces Investment by CinRx Pharma | vTv Therapeutics Inc.
- vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes | vTv Therapeutics Inc.
- vTv Therapeutics Announces Investment by and Entry into Collaboration and License Agreement with affiliates of G42 Healthcare | vTv Therapeutics Inc.
- Sign Up | LinkedIn
- vTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update | vTv Therapeutics Inc.
- In The News - VTV Therapeutics
- vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes | vTv Therapeutics Inc.
- vTv Therapeutics to Present Additional Positive Clinical Study Results from Phase 2 Simplici-T1 Study of TTP399 as Adjunctive Therapy for Patients with Type 1 Diabetes at EASD Virtual Meeting | vTv Therapeutics Inc.
- vTv Therapeutics Announces Appointment of Edward P. Taibi to its Board of Directors | vTv Therapeutics Inc.
- View more press releases Close
Redes sociales sobre vTv Therapeutics
- vTv Therapeutics en Wikipedia, Google News y Yahoo Finance
- vTv Therapeutics en LinkedIn, Twitter y YouTube
Ponerse en contacto
Contactar a través de e-mail con sus ejecutivos Paul Sekhri 
Llame a vTv Therapeutics al +1 336...
